OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Entry into a Material Definitive Agreement

44

OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

(d) Exhibits

Exhibit No.

Description

99.1 Press Release of OPKO dated October 12, 2017

ExhibitIndex

Exhibit No.

Description

99.1 Press Release of OPKO dated October 12, 2017


Opko Health, Inc. Exhibit
EX-99.1 2 d454644dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan OPKO to receive up to $118 million in upfront and milestone payments,…
To view the full exhibit click here

About OPKO Health, Inc. (NASDAQ:OPK)

OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.

An ad to help with our costs